• Organizations: STAAR Surgical
FDA approves expanded age indication for STAAR's EVO/EVO+ Visian ICLs
Products

FDA approves expanded age indication for STAAR's EVO/EVO+ Visian ICLs

U.S. age indication now includes patients aged 21 to 60 years old, making nearly 8 million refractive patients eligible for implantable collamer lens implantation.
Leadership watch: Staar Surgical names co-CEOs, ACET adds to Board
Business

Leadership watch: Staar Surgical names co-CEOs, ACET adds to Board

Leadership changes are underway in the eyecare space—and we’ve got the latest.
STAAR Surgical and Alcon terminate proposed merger
Business

STAAR Surgical and Alcon terminate proposed merger

Decision to end the estimated $1.6 billion deal follows a failed vote among STAAR stockholders earlier this week.
Alcon proposes higher bid for STAAR Surgical acquisition
Business

Alcon proposes higher bid for STAAR Surgical acquisition

Amended merger agreement increases total equity value of deal by $150 million; meanwhile, a major shareholder is urging against the sale.
Alcon to acquire STAAR Surgical
Business

Alcon to acquire STAAR Surgical

The $1.5 billion deal includes STAAR’s FDA-approved implantable collamer lenses; expected to close within 6 to 12 months.
Staar Surgical appoints new CEO amid leadership changes
Business

Staar Surgical appoints new CEO amid leadership changes

Global healthcare executive veteran Stephen C. Farrell takes over the helm as Elizabeth Yeu, MD, is named board chair of STAAR’s Board of Directors.
The FDA has approved the EVO Visian ICL.
Archives

The FDA has approved the EVO Visian ICL.

A new ICL is here!